Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)

Fischer K. et al, (2024), Research and Practice in Thrombosis and Haemostasis, 8

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.

Madan B. et al, (2024), J Thromb Haemost

Multiple myeloma and its treatment contribute to increased platelet reactivity.

Mitchell JL. et al, (2023), Platelets, 34

Frailty and haemophilia; speaking the language of geriatricians.

Sangha G. et al, (2023), Haemophilia, 29, 1371 - 1375

Platelet factor XIII-A regulates platelet function and promotes clot retraction and stability

Mitchell JL. et al, (2023), Research and Practice in Thrombosis and Haemostasis, 7

Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries.

Funding E. et al, (2023), Adv Ther

Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO).

Wall C. et al, (2023), Haemophilia, 29, 743 - 752

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.

Mahlangu J. et al, (2023), N Engl J Med, 388, 694 - 705

Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.

Zwagemaker A-F. et al, (2022), J Thromb Haemost

Safety and pharmacokinetic profile of apixaban in end‐stage renal disease: A real‐world analysis

Tseng CI. et al, (2022), eJHaem

GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements.

Dixon PH. et al, (2022), Nat Commun, 13

Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.

Chowdary P. et al, (2022), N Engl J Med, 387, 237 - 247

The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.

Whyte CS. et al, (2022), J Thromb Haemost

Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress.

Ariëns RA. et al, (2022), Res Pract Thromb Haemost, 6

The bleeding phenotype in people with non-severe hemophilia.

Kloosterman FR. et al, (2022), Blood Adv

Risk of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination prior to the recognition of vaccine-induced thrombocytopenia and thrombosis: A self-controlled case series study in England.

Higgins H. et al, (2022), Res Pract Thromb Haemost, 6

Cardiovascular disease in hereditary haemophilia: The challenges of longevity.

Shapiro S. et al, (2022), Br J Haematol

Factor IX Expression within the Normal Range Prevents Spontaneous Bleeds Requiring Treatment Following FLT180a Gene Therapy in Patients with Severe Hemophilia B: Long-Term Follow- up Study of the B-Amaze Program

Chowdary P. et al, (2021), BLOOD, 138

Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial

Pipe SW. et al, (2021), BLOOD, 138

Incidence of symptomatic image-confirmed venous thromboembolism in outpatients managed in a hospital-led COVID-19 virtual ward.

Shapiro S. et al, (2021), EJHaem, 2, 794 - 798

Load More

Include forthcoming?